JP2016535098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535098A5 JP2016535098A5 JP2016551069A JP2016551069A JP2016535098A5 JP 2016535098 A5 JP2016535098 A5 JP 2016535098A5 JP 2016551069 A JP2016551069 A JP 2016551069A JP 2016551069 A JP2016551069 A JP 2016551069A JP 2016535098 A5 JP2016535098 A5 JP 2016535098A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899903P | 2013-11-05 | 2013-11-05 | |
| US61/899,903 | 2013-11-05 | ||
| PCT/GB2014/053236 WO2015067923A1 (en) | 2013-11-05 | 2014-10-30 | Nmda antagonist prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019018440A Division JP6633233B2 (ja) | 2013-11-05 | 2019-02-05 | Ｎｍｄａアンタゴニストプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535098A JP2016535098A (ja) | 2016-11-10 |
| JP2016535098A5 true JP2016535098A5 (enExample) | 2019-01-24 |
| JP6479834B2 JP6479834B2 (ja) | 2019-03-06 |
Family
ID=51947383
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551069A Active JP6479834B2 (ja) | 2013-11-05 | 2014-10-30 | Ｎｍｄａアンタゴニストプロドラッグ |
| JP2019018440A Active JP6633233B2 (ja) | 2013-11-05 | 2019-02-05 | Ｎｍｄａアンタゴニストプロドラッグ |
| JP2019222567A Active JP6856737B2 (ja) | 2013-11-05 | 2019-12-10 | Ｎｍｄａアンタゴニストプロドラッグ |
| JP2021044193A Active JP7234278B2 (ja) | 2013-11-05 | 2021-03-18 | Ｎｍｄａアンタゴニストプロドラッグ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019018440A Active JP6633233B2 (ja) | 2013-11-05 | 2019-02-05 | Ｎｍｄａアンタゴニストプロドラッグ |
| JP2019222567A Active JP6856737B2 (ja) | 2013-11-05 | 2019-12-10 | Ｎｍｄａアンタゴニストプロドラッグ |
| JP2021044193A Active JP7234278B2 (ja) | 2013-11-05 | 2021-03-18 | Ｎｍｄａアンタゴニストプロドラッグ |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9822075B2 (enExample) |
| EP (3) | EP4001272B1 (enExample) |
| JP (4) | JP6479834B2 (enExample) |
| KR (2) | KR102336426B1 (enExample) |
| CN (2) | CN105683180B (enExample) |
| AR (1) | AR098319A1 (enExample) |
| AU (1) | AU2014345407B2 (enExample) |
| CA (1) | CA2928004C (enExample) |
| CY (1) | CY1121749T1 (enExample) |
| DK (1) | DK3066091T3 (enExample) |
| ES (3) | ES2894903T3 (enExample) |
| HR (2) | HRP20191159T1 (enExample) |
| HU (2) | HUE045001T2 (enExample) |
| LT (1) | LT3066091T (enExample) |
| MX (2) | MX377276B (enExample) |
| PL (2) | PL4001272T3 (enExample) |
| PT (1) | PT3066091T (enExample) |
| RS (2) | RS66369B1 (enExample) |
| RU (1) | RU2695372C2 (enExample) |
| SI (1) | SI3066091T1 (enExample) |
| SM (1) | SMT202500023T1 (enExample) |
| TR (1) | TR201909632T4 (enExample) |
| TW (1) | TW201609653A (enExample) |
| UY (1) | UY35823A (enExample) |
| WO (1) | WO2015067923A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3066091T3 (da) | 2013-11-05 | 2019-07-15 | Astrazeneca Ab | Nmda-antagonist-prodrugs |
| WO2018098344A1 (en) * | 2016-11-28 | 2018-05-31 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| CN107578281B (zh) * | 2017-08-31 | 2021-03-30 | 湖南大学 | 电子商务环境下用户优惠券行为预测方法及模型构建方法 |
| MX2022016183A (es) | 2020-06-23 | 2023-02-13 | Biohaven Therapeutics Ltd | Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina. |
| WO2025137661A1 (en) * | 2023-12-22 | 2025-06-26 | Biohaven Therapeutics Ltd. | Combination treatment of neurological disorders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7909514L (sv) | 1979-11-16 | 1981-05-17 | Astra Laekemedel Ab | Nya halofenyl-pyridyl-allylaminderivat |
| US4769466A (en) | 1987-02-06 | 1988-09-06 | Pennwalt Corporation | 2-aminoacetamide pyridinyl derivatives |
| EP0356035B1 (en) * | 1988-08-12 | 1996-03-13 | Astra Aktiebolag | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
| EP0540318A1 (en) | 1991-10-30 | 1993-05-05 | Fisons Corporation | 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals |
| KR100259567B1 (ko) * | 1992-04-03 | 2000-07-01 | 클래스 빌헬름슨 | 신경변성 질환 치료용 1-페닐-2-(2-피리디닐)에틸아민 에난티오머 |
| SE9901077D0 (sv) | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| US6613879B1 (en) * | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| PA8525601A1 (es) | 2000-08-21 | 2002-04-25 | Hoffmann La Roche | Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol |
| WO2002100347A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| CA2551859C (en) | 2003-12-30 | 2011-10-04 | Xenoport, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| CA2621847A1 (en) * | 2005-09-08 | 2007-03-15 | Shire Llc | Prodrugs of t3 and t4 with enhanced bioavailability |
| CN101246417B (zh) | 2007-02-13 | 2010-09-29 | 艾威梯科技(北京)有限公司 | 音频数据流输入/输出无间断软件切换的方法和系统 |
| JP5563483B2 (ja) | 2008-01-25 | 2014-07-30 | ゼノポート，インコーポレイティド | アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解 |
| US8299291B2 (en) | 2008-08-07 | 2012-10-30 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| US9062094B2 (en) * | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| WO2013023155A1 (en) * | 2011-08-11 | 2013-02-14 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use |
| DK3066091T3 (da) | 2013-11-05 | 2019-07-15 | Astrazeneca Ab | Nmda-antagonist-prodrugs |
-
2014
- 2014-10-30 DK DK14802476.3T patent/DK3066091T3/da active
- 2014-10-30 SM SM20250023T patent/SMT202500023T1/it unknown
- 2014-10-30 TR TR2019/09632T patent/TR201909632T4/tr unknown
- 2014-10-30 ES ES19166031T patent/ES2894903T3/es active Active
- 2014-10-30 SI SI201431242T patent/SI3066091T1/sl unknown
- 2014-10-30 KR KR1020167014625A patent/KR102336426B1/ko active Active
- 2014-10-30 HU HUE14802476A patent/HUE045001T2/hu unknown
- 2014-10-30 WO PCT/GB2014/053236 patent/WO2015067923A1/en not_active Ceased
- 2014-10-30 PL PL21196371.5T patent/PL4001272T3/pl unknown
- 2014-10-30 CN CN201480060416.0A patent/CN105683180B/zh active Active
- 2014-10-30 PL PL14802476T patent/PL3066091T3/pl unknown
- 2014-10-30 EP EP21196371.5A patent/EP4001272B1/en active Active
- 2014-10-30 EP EP19166031.5A patent/EP3564234B1/en active Active
- 2014-10-30 MX MX2016005567A patent/MX377276B/es active IP Right Grant
- 2014-10-30 CN CN202010014023.3A patent/CN111187202B/zh active Active
- 2014-10-30 RS RS20241459A patent/RS66369B1/sr unknown
- 2014-10-30 US US15/034,727 patent/US9822075B2/en active Active
- 2014-10-30 LT LTEP14802476.3T patent/LT3066091T/lt unknown
- 2014-10-30 CA CA2928004A patent/CA2928004C/en active Active
- 2014-10-30 PT PT14802476T patent/PT3066091T/pt unknown
- 2014-10-30 HU HUE21196371A patent/HUE070532T2/hu unknown
- 2014-10-30 RU RU2016119493A patent/RU2695372C2/ru active
- 2014-10-30 EP EP14802476.3A patent/EP3066091B1/en active Active
- 2014-10-30 HR HRP20191159TT patent/HRP20191159T1/hr unknown
- 2014-10-30 AU AU2014345407A patent/AU2014345407B2/en active Active
- 2014-10-30 JP JP2016551069A patent/JP6479834B2/ja active Active
- 2014-10-30 ES ES14802476T patent/ES2733344T3/es active Active
- 2014-10-30 ES ES21196371T patent/ES2999064T3/es active Active
- 2014-10-30 KR KR1020217039470A patent/KR102469167B1/ko active Active
- 2014-10-30 HR HRP20241784TT patent/HRP20241784T1/hr unknown
- 2014-10-30 MX MX2020011946A patent/MX394633B/es unknown
- 2014-10-30 RS RS20190821A patent/RS58991B1/sr unknown
- 2014-11-05 AR ARP140104166A patent/AR098319A1/es unknown
- 2014-11-05 UY UY0001035823A patent/UY35823A/es not_active Application Discontinuation
- 2014-11-05 TW TW103138423A patent/TW201609653A/zh unknown
-
2017
- 2017-10-17 US US15/785,654 patent/US10207994B2/en active Active
-
2019
- 2019-01-20 US US16/252,648 patent/US10815199B2/en active Active
- 2019-02-05 JP JP2019018440A patent/JP6633233B2/ja active Active
- 2019-07-02 CY CY20191100691T patent/CY1121749T1/el unknown
- 2019-12-10 JP JP2019222567A patent/JP6856737B2/ja active Active
-
2020
- 2020-10-26 US US17/079,553 patent/US12516023B2/en active Active
-
2021
- 2021-03-18 JP JP2021044193A patent/JP7234278B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535098A5 (enExample) | ||
| NZ603236A (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
| JP2012532874A5 (enExample) | ||
| UA107112C2 (uk) | Активатори розчинної гуанілатциклази | |
| NZ626985A (en) | Combination therapy (vemurafenib and a mdm2 inhibitor) for the treatment proliferative disorders | |
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| EA201100928A1 (ru) | Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов | |
| SG10201405826RA (en) | Inhibitors of influenza viruses replication | |
| NZ595168A (en) | Hepatitis c virus inhibitors | |
| JP2008255122A5 (enExample) | ||
| RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
| BR112014010420A2 (pt) | inibidores de pak para o tratamento de distúrbios proliferativos celulares | |
| MX360030B (es) | Metodos para tratar el trastorno bipolar. | |
| EA201391337A1 (ru) | Ингибиторы hsp90 | |
| JP2012519182A5 (enExample) | ||
| JP2011523952A5 (enExample) | ||
| NZ593524A (en) | A nonapeptide with anti-tumour activity | |
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| PE20110677A1 (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275) | |
| RU2016119493A (ru) | Пролекарства антагониста NMDA | |
| CY1118036T1 (el) | Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων | |
| AR090592A1 (es) | Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona | |
| JP2014519507A5 (enExample) | ||
| MA35347B1 (fr) | Procedes therapeuiques |